Citations (2)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Carlo Lazzaro, Nicola Amedeo Mazzanti, Silvia Rossi & Fabio Parazzini. (2023) Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model. Expert Review of Pharmacoeconomics & Outcomes Research 23:10, pages 1185-1200.
Read now
Read now
Jenniina Harno-Tasihin, Laura Siregar, Mikko Paajanen, Perttu Arkkila & Jari Punkkinen. Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses. Scandinavian Journal of Gastroenterology 0:0, pages 1-8.
Read now
Read now